Background Whether non–vitamin K antagonist oral anticoagulants (NOAC s) are superior to
warfarin among Asians with nonvalvular atrial fibrillation remains unclear. Methods and …

Objectives: There is scarce evidence comparing novel oral anticoagulants (NOACs) with
warfarin in real-world settings in Japan. This study compared the risk of bleeding events …

Background: It is unclear whether the non–vitamin K antagonist oral anticoagulant agents
rivaroxaban and dabigatran are superior to warfarin for efficacy and safety outcomes in …

Objective To compare effectiveness and safety of warfarin and the direct oral anticoagulants
(DOAC) dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation in routine …

Background Whether four direct oral anticoagulants (DOACs) are superior to warfarin in
Asian patients with nonvalvular atrial fibrillation (NVAF) remains unclear. Methods This …

Background and Purpose—This ARISTOPHANES study (Anticoagulants for Reduction in
Stroke: Observational Pooled Analysis on Health Outcomes and Experience of Patients) …

Background Stroke is the most serious clinical consequence of atrial fibrillation, which is the
most common cardiac arrhythmia. Non-vitamin K antagonist oral anticoagulants (NOACs) …

Background The introduction of non–vitamin K antagonist oral anticoagulants has been a
major advance for stroke prevention in atrial fibrillation; however, outcomes achieved in …

Background and Purpose—Limited data are available describing the relative effectiveness,
safety, and optimal dosing of non–vitamin K antagonist oral anticoagulants (NOACs) for …

Background and Purpose: The effects of direct oral anticoagulants in nonvalvular atrial
fibrillation should be assessed in actual conditions of use. France has near-universal …